Novo Nordisk: wins Canada approval for haemophilia drug
(CercleFinance.com) - Danish drugmaker Novo Nordisk said that Health Canada has approved its Esperoct drug for use in adults and children with haemophilia A.
The drug - that helps people with haemophilia A better manage their bleeding episodes - has been approved for routine prophylaxis to prevent or reduce the frequency of these episodes, the company said.
Esperoct has also been approved for on-demand treatment and control of bleeding episodes, and perioperative management of bleeding, it said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The drug - that helps people with haemophilia A better manage their bleeding episodes - has been approved for routine prophylaxis to prevent or reduce the frequency of these episodes, the company said.
Esperoct has also been approved for on-demand treatment and control of bleeding episodes, and perioperative management of bleeding, it said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.